Koyfin Home > Directory > Health Care > Adma Biologics > Total Debt / (EBITDA-CAPEX)

Adma Biologics Total Debt / (EBITDA-CAPEX) Chart (ADMA)

Adma Biologics annual/quarterly Total Debt / (EBITDA-CAPEX) from 2010 to 2020.
  • Adma Biologics Total Debt / (EBITDA-CAPEX) for the quarter ending June 06, 2020 was $-1m a -69.94% increase of 1m year over year
  • Adma Biologics Total Debt / (EBITDA-CAPEX) for the last 12 months ending June 06, 2020 was $-2m a 4.49% decrease of 0m year over year
  • Adma Biologics Annual Total Debt / (EBITDA-CAPEX) for 2019 was $-2m a 65.64% decrease of -1m from 2018
  • Adma Biologics Annual Total Debt / (EBITDA-CAPEX) for 2018 was $-1m a -37.57% increase of 0m from 2017
  • Adma Biologics Annual Total Debt / (EBITDA-CAPEX) for 2017 was $-1m a -12.47% increase of 0m from 2016
Other Ratios Metrics:
  • Adma Biologics Total Debt / Capital for the quarter ending September 09, 2018 was $53m a 4.96% increase of 3m year over year
  • Adma Biologics Other Liabilities for the quarter ending December 12, 2018 was $18m a -0.86% decrease of 0m year over year
  • Adma Biologics Total Debt / Equity for the quarter ending September 09, 2018 was $111m a 9.91% increase of 11m year over year
View Chart On Koyfin

Quarterly ADMA Total Debt / (EBITDA-CAPEX) Data

06/2020$-1m
03/2020$-1m
12/2019$-3m
09/2019$-2m
06/2019$-2m
03/2019$-1m
12/2018$-1m
09/2018$-1m
06/2018$-1m
03/2018$-1m

Annual ADMA Total Debt / (EBITDA-CAPEX) Data

2019$-2m
2018$-1m
2017$-1m
2016$-1m
2015$-1m
2014$-1m
2013$0m
2012$0m
2011$0m
2010$-1m